Evidence map›Paper›PMID 41652222›Full record

Trial reportBritish journal of cancer2026

Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.

Benoit Blanchet, Alicja Puszkiel, Anne Jouinot, Mostefa Bennamoun, Denis Maillet, Delphine Borchiellini, Brigitte Laguerre, Diane Pannier, Marine Gross-Goupil, Christine Chevreau and 10 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Benoit BlanchetBiologie du Médicament-Toxicologie, Hôpital Cochin, Institut du Cancer Paris CARPEM, AP-HP. Centre - Université Paris Cité, Paris, France. benoit.blanchet@aphp.fr.ORCID http://orcid.org/0000-0003-3096-4305
Alicja PuszkielBiologie du Médicament-Toxicologie, Hôpital Cochin, Institut du Cancer Paris CARPEM, AP-HP. Centre - Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0003-2954-4418
Anne JouinotUniversité Paris Cité, CNRS, INSERM, Institut Cochin, F-75014, Paris, France.ORCID http://orcid.org/0000-0002-7922-2065
Mostefa BennamounDepartment of Medical Oncology, Institut Mutualiste Montsouris, Paris, France.
Denis MailletDepartment of Medical Oncology, IMMUCARE, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices de Lyon (IC-HCL), Pierre-Bénite, France.
Delphine BorchielliniDepartment of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.
Brigitte LaguerreDepartment of Medical Oncology, Centre Eugene - Marquis, Rennes, France.
Diane PannierDepartment of Medical Oncology, Centre Oscar Lambret, Lille, France.
Marine Gross-GoupilDepartment of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux - Hôpital Saint-André, Bordeaux, France.
Christine ChevreauDepartment of Medical Oncology, Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, France.
Philippe BarthélémyDepartment of Medical Oncology, Hôpitaux universitaires de Strasbourg, Strasbourg, France.
Christophe TournigandDepartment of Medical Oncology, Hôpital Henri-Mondor, AP-HP Centre - Université de Paris Est, Créteil, France.
Elodie CoquanDepartment of Medical Oncology, Centre de Lutte Contre le Cancer François Baclesse, Caen, France.
Gwenaelle GravisDepartment of Medical Oncology, Institut Paoli-Calmettes, Aix Marseille Univ, INSERM, CNRS, CRCM, Immunity and Cancer Team, Marseille, France.ORCID http://orcid.org/0000-0002-3127-1554
Eve LepicardARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie (ARTIC), Hôpital Européen Georges Pompidou, AP-HP. Centre - Université Paris Cité, Paris, France.
Wolf Herman FridmanCentre de Recherche des Cordeliers, INSERM, Equipe labellisée Ligue contre le Cancer, Université Paris Cité, Sorbonne Université, Paris, France.
Catherine Sautes-FridmanCentre de Recherche des Cordeliers, INSERM, Equipe labellisée Ligue contre le Cancer, Université Paris Cité, Sorbonne Université, Paris, France.
Stéphane OudardDepartment of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP. Centre - Université Paris Cité, Paris, France.
Cheng-Ming SunCentre de Recherche des Cordeliers, INSERM, Equipe labellisée Ligue contre le Cancer, Université Paris Cité, Sorbonne Université, Paris, France.
Yann-Alexandre VanoCentre de Recherche des Cordeliers, INSERM, Equipe labellisée Ligue contre le Cancer, Université Paris Cité, Sorbonne Université, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to investigate the exposure-response (E/R) relationship for ipilimumab and nivolumab in metastatic clear cell renal cell carcinoma (m-ccRCC) patients from the randomised phase 2 BIONIKK trial (EudraCT 2016-003099-28).

methodsThis study included patients treated with either single-agent nivolumab (Nivo monotherapy group, n = 39) or nivolumab plus ipilimumab (Ipi/Nivo group, n = 71). Trough plasma concentrations (C

resultsLow nivolumab C

conclusionsThis study suggests an E-R relationship for the efficacy of ipilimumab in m-ccRCC patients treated in combination with nivolumab. Prospective validation of our efficacy threshold in larger cohorts or phase 3 trials is essential prior to the implementation of a pharmacokinetically guided strategy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellIpilimumabKidney NeoplasmsNivolumabAdultAgedFemaleHumansMaleMiddle AgedIpilimumabNivolumab

Identifiers

PMID41652222
PMCPMC13036070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.